| You are here: Home: BCU 1|2004: Harold J Burstein, MD, PhD: Select publications
Select publications
Publications discussed by Dr Burstein
Boccardo F et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003;Abstract 3.
Boccardo F et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: Results of an Italian cooperative study. J Clin Oncol 2001;19(22):4209-15.Abstract.
Bryant J, Wolmark N. Letrozole after tamoxifen for breast cancer-What is the price of success? N Engl J Med 2003;349(19):1855-7. No abstract available.
Burstein HJ. Beyond tamoxifen-Extending endocrine treatment for early-stage breast cancer. N Engl J Med 2003;349(19):1857-9. No abstract available.
Burstein HJ et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2-overexpressing stage II or III breast cancer: A pilot study. J Clin Oncol 2003;21(1):46-53. Abstract.
Burstein HJ et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter Phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21(15):2889-95. Abstract
Costanza ME et al. Safety and efficacy of using a single agent or a Phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: Report of a randomized study-Cancer and Leukemia Group B 8642. J Clin Oncol 1999;17(5):1397-406. Abstract
Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract
Harris L et al. Preoperative trastuzumab and vinorelbine (HN) is a highly active, well-tolerated regimen for HER2 3+/FISH+ Stage II/III breast cancer. Proc ASCO 2003;Abstract 86.
O'Shaughnessy JA et al. Randomized, open-label, Phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12(9):1247-54. Abstract
Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract
Sledge GW et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup trial (E1193). J Clin Oncol 2003;21(4):588-92. Abstract
Talbot DC et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86(9):1367-72. Abstract
Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract
|
